JP2017536119A5 - - Google Patents

Download PDF

Info

Publication number
JP2017536119A5
JP2017536119A5 JP2017526918A JP2017526918A JP2017536119A5 JP 2017536119 A5 JP2017536119 A5 JP 2017536119A5 JP 2017526918 A JP2017526918 A JP 2017526918A JP 2017526918 A JP2017526918 A JP 2017526918A JP 2017536119 A5 JP2017536119 A5 JP 2017536119A5
Authority
JP
Japan
Prior art keywords
lna
nucleosides
oligonucleotide according
nucleoside
phosphorothioate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017526918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536119A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/076967 external-priority patent/WO2016079181A1/en
Publication of JP2017536119A publication Critical patent/JP2017536119A/ja
Publication of JP2017536119A5 publication Critical patent/JP2017536119A5/ja
Pending legal-status Critical Current

Links

JP2017526918A 2014-11-19 2015-11-18 キラルホスホロチオエート連結を含むlnaギャップマーオリゴヌクレオチド Pending JP2017536119A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
EP14193887.8 2014-11-19
EP14193887 2014-11-19
EP14198167 2014-12-16
EP14198167.0 2014-12-16
EP15182401 2015-08-25
EP15182401.8 2015-08-25
EP15191075 2015-10-22
EP15191076.7 2015-10-22
EP15191075.9 2015-10-22
EP15191076 2015-10-22
EP15191074 2015-10-22
EP15191074.2 2015-10-22
PCT/EP2015/076967 WO2016079181A1 (en) 2014-11-19 2015-11-18 Lna gapmer oligonucleotides comprising chiral phosphorothioate linkages

Publications (2)

Publication Number Publication Date
JP2017536119A JP2017536119A (ja) 2017-12-07
JP2017536119A5 true JP2017536119A5 (enExample) 2018-11-15

Family

ID=54608516

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017526918A Pending JP2017536119A (ja) 2014-11-19 2015-11-18 キラルホスホロチオエート連結を含むlnaギャップマーオリゴヌクレオチド
JP2017526905A Pending JP2017536366A (ja) 2014-11-19 2015-11-18 Lnaキラルホスホロチオエート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017526905A Pending JP2017536366A (ja) 2014-11-19 2015-11-18 Lnaキラルホスホロチオエート

Country Status (4)

Country Link
US (2) US20180016575A1 (enExample)
EP (2) EP3220921A1 (enExample)
JP (2) JP2017536119A (enExample)
WO (2) WO2016079181A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
DK2872485T3 (da) 2012-07-13 2021-03-08 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
CN112007045B (zh) 2012-07-13 2026-01-06 波涛生命科学有限公司 手性控制
JP6246121B2 (ja) 2012-07-13 2017-12-13 株式会社新日本科学 キラル核酸アジュバント
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
KR102423317B1 (ko) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 키랄 디자인
ES2810375T3 (es) 2014-12-17 2021-03-08 Proqr Therapeutics Ii Bv Edición direccionada de ARN
WO2016112132A1 (en) * 2015-01-06 2016-07-14 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
WO2016167780A1 (en) 2015-04-16 2016-10-20 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
WO2017015575A1 (en) 2015-07-22 2017-01-26 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
US10955407B2 (en) 2015-10-22 2021-03-23 Roche Innovation Center Copenhagen A/S In vitro toxicity screening assay
US11267843B2 (en) * 2016-03-18 2022-03-08 Roche Innovation Center Copenhagen A/S Stereodefining L-monomers
JP2019516680A (ja) 2016-05-04 2019-06-20 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. オリゴヌクレオチド組成物およびその方法
AU2017285350A1 (en) 2016-06-17 2018-12-20 F. Hoffmann-La Roche Ag Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infection
WO2017216325A1 (en) * 2016-06-17 2017-12-21 F. Hoffmann-La Roche Ag In vitro nephrotoxicity screening assay
JP7049271B2 (ja) * 2016-06-17 2022-04-06 エフ.ホフマン-ラ ロシュ アーゲー インビトロ腎毒性スクリーニングアッセイ
EP3475424A1 (en) 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
CA3035293A1 (en) 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
US11542292B2 (en) 2016-11-14 2023-01-03 Tokyo University Of Science Foundation Polymerizable compound, compound, and method for producing boranophosphate oligomer
JP7296882B2 (ja) * 2016-11-23 2023-06-23 ウェイブ ライフ サイエンシズ リミテッド ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法
WO2018130583A1 (en) * 2017-01-13 2018-07-19 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating nfkb1 expression
WO2018130585A1 (en) * 2017-01-13 2018-07-19 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating relb expression
EP3571300A1 (en) 2017-01-19 2019-11-27 ProQR Therapeutics II B.V. Oligonucleotide complexes for use in rna editing
CN111226114A (zh) 2017-10-13 2020-06-02 罗氏创新中心哥本哈根有限公司 用部分立体限定的寡核苷酸子文库鉴定反义寡核苷酸改进的立体限定硫代磷酸酯寡核苷酸变体的方法
CN111511914B (zh) * 2017-10-16 2023-11-17 豪夫迈·罗氏有限公司 减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染
WO2019109001A1 (en) 2017-12-01 2019-06-06 The Texas A&M University System Angelman syndrome antisense treatment
CA3084170A1 (en) * 2017-12-22 2019-06-27 Roche Innovation Center Copenhagen A/S Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
JP2021508327A (ja) * 2017-12-22 2021-03-04 ロシュ イノベーション センター コペンハーゲン エーエス 新規のチオホスホラミダイト
TW201929870A (zh) * 2017-12-22 2019-08-01 丹麥商羅氏創新中心哥本哈根有限公司 包含二硫代磷酸酯核苷間連結之寡核苷酸
US12241065B2 (en) * 2018-01-12 2025-03-04 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
CN120310791A (zh) 2018-01-12 2025-07-15 百时美施贵宝公司 靶向α-突触核蛋白的反义寡核苷酸及其用途
CA3096682A1 (en) 2018-04-13 2019-10-17 Bristol-Myers Squibb Company Novel phosphorous (v)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (v) compounds
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
WO2020007892A1 (en) 2018-07-03 2020-01-09 F. Hoffmann-La Roche Ag Oligonucleotides for modulating tau expression
CN112469827B (zh) * 2018-07-04 2024-05-24 学校法人爱知医科大学 控制Tau的剪接的反义寡核苷酸及其用途
CA3130431A1 (en) * 2019-02-20 2020-08-27 Roche Innovation Center Copenhagen A/S Phosphonoacetate gapmer oligonucleotides
EP3976056A2 (en) 2019-05-31 2022-04-06 Aligos Therapeutics, Inc. Modified gapmer oligonucleotides and methods of use
EP4090664A4 (en) 2020-01-16 2024-05-22 Bristol-Myers Squibb Company REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS
MX2023011101A (es) * 2021-03-26 2024-01-10 Neumirna Therapeutics Aps Inhibidores de microrna-27b.
CN120187734A (zh) 2022-09-19 2025-06-20 百时美施贵宝公司 新的基于磷(v)的试剂、其制备方法以及其在制备立体定义的有机磷(v)化合物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242589B1 (en) * 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
CA2667055C (en) * 2006-10-18 2017-05-09 Isis Pharmaceuticals, Inc. Antisense compounds
CN112007045B (zh) * 2012-07-13 2026-01-06 波涛生命科学有限公司 手性控制
US20150368642A1 (en) * 2013-01-30 2015-12-24 Hoffmann-La Roche Inc. Lna oligonucleotide carbohydrate conjugates

Similar Documents

Publication Publication Date Title
JP2017536366A5 (enExample)
JP2020058368A5 (enExample)
IL300119A (en) Oligonucleotides to induce paternal UBE3A expression
JP2016116520A5 (enExample)
JP2018512110A5 (enExample)
JP2020022483A5 (enExample)
JP2018512041A5 (enExample)
JP2020532961A5 (enExample)
JP2013226147A5 (enExample)
JP2017505623A5 (enExample)
JP2012510297A5 (enExample)
JP2013511990A5 (enExample)
JP2021505129A5 (enExample)
HRP20210315T1 (hr) Oligonukleotidi za smanjenje ekspresije pd-l1
JP2009524419A5 (enExample)
JP2015514418A5 (enExample)
JP2016530294A5 (enExample)
JP2016171800A5 (enExample)
JP2019503394A5 (enExample)
JP2013535212A5 (enExample)
JP2014511686A5 (enExample)
JP2012105686A5 (enExample)
JP2009532044A5 (enExample)
JP2018525357A5 (enExample)
JP2016520310A5 (enExample)